Regenxbio Inc (NASDAQ:RGNX) hit a new 52-week high during trading on Tuesday . The stock traded as high as $72.65 and last traded at $72.85, with a volume of 16418 shares. The stock had previously closed at $71.95.
RGNX has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Thursday, March 8th. BidaskClub lowered shares of Regenxbio from a “buy” rating to a “hold” rating in a report on Tuesday, March 13th. Morgan Stanley dropped their target price on shares of Regenxbio from $36.00 to $35.00 and set an “overweight” rating for the company in a report on Wednesday, March 14th. ValuEngine raised shares of Regenxbio from a “sell” rating to a “hold” rating in a report on Wednesday, April 4th. Finally, Chardan Capital upped their target price on shares of Regenxbio from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, April 9th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $47.13.
The firm has a market capitalization of $2.27 billion, a PE ratio of -30.10, a price-to-earnings-growth ratio of 9.48 and a beta of -1.03.
Regenxbio (NASDAQ:RGNX) last released its earnings results on Tuesday, May 8th. The biotechnology company reported $3.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.00 by $2.04. Regenxbio had a net margin of 37.28% and a return on equity of 23.27%. The business had revenue of $132.39 million during the quarter, compared to analyst estimates of $80.00 million. analysts predict that Regenxbio Inc will post 1.89 EPS for the current year.
In related news, CFO Vittal Vasista sold 5,000 shares of the company’s stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $37.56, for a total value of $187,800.00. Following the completion of the sale, the chief financial officer now owns 154,434 shares of the company’s stock, valued at $5,800,541.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Patrick J. Christmas sold 10,000 shares of the company’s stock in a transaction dated Wednesday, April 11th. The shares were sold at an average price of $39.00, for a total transaction of $390,000.00. Following the completion of the sale, the senior vice president now directly owns 11,141 shares of the company’s stock, valued at approximately $434,499. The disclosure for this sale can be found here. Insiders sold 100,100 shares of company stock valued at $4,780,125 in the last three months. 16.90% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in RGNX. Schwab Charles Investment Management Inc. grew its holdings in shares of Regenxbio by 4.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 128,187 shares of the biotechnology company’s stock valued at $4,263,000 after purchasing an additional 5,678 shares during the period. Teacher Retirement System of Texas purchased a new stake in shares of Regenxbio in the fourth quarter valued at about $302,000. Royce & Associates LP purchased a new stake in shares of Regenxbio in the fourth quarter valued at about $1,962,000. Hudson Bay Capital Management LP grew its holdings in shares of Regenxbio by 275.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 75,000 shares of the biotechnology company’s stock valued at $2,494,000 after purchasing an additional 55,000 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Regenxbio by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 248,328 shares of the biotechnology company’s stock valued at $8,256,000 after purchasing an additional 2,506 shares during the period. 69.92% of the stock is owned by hedge funds and other institutional investors.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.